Drugs / Tumor Cell Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01258868 | Dec 2010 → Jun 2016 | esophageal cancer, lung cancer, mesothelioma, sarcoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00148993 | Jul 1998 → Jul 2005 | metastatic neoplasm | Hadassah Medical Organization | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01258868 ↗ |
| Modality | Vaccine | “returning the cells to the patient as a vaccine to encourage the immune system to respond to them.” NCT01258868 ↗ |
| Route | Intramuscular | “emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections” NCT01258868 ↗ |